|
US2011060120A1
|
|
Immunogenic treatment of cancer by peptides inducing the plasma membrane exposure of erp57
|
|
WO2008032153A2
|
|
Calreticulin for its use as a medication for the treatment of cancer in a mammal
|
|
US2009004172A1
|
|
Service for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using erp57 translocation
|
|
US2009004678A1
|
|
Method for screening fertility and new compounds or molecules, using crt or erp57 translocation
|
|
US2009004178A1
|
|
Pharmaceutical compound for blocking the crt or erp57 translocation
|
|
US2009048159A1
|
|
Kit for treating a health condition by inducing translocation of a calreticulin protein to a cellular membrane
|
|
US2009010952A1
|
|
Pharmaceutical compound for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt or erp57 translocation
|
|
US2009004134A1
|
|
Kit for treating a health condition by inducing translocation of an erp57 protein to a cellular membrane
|
|
US2008214452A1
|
|
Method for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt translocation
|
|
US2009005305A1
|
|
Service for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt translocation
|
|
US2009004211A1
|
|
Method for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using erp57 translocation
|
